The CT-0508 study is sponsored by Carisma Therapeutics. It is a Phase 1, first in human clinical research study to explore the safety and tolerability of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpression in solid tumors. This study is currently taking place in the US with 5 total study locations in California, North Carolina, Pennsylvania, Tennessee, and Texas.
CT-0508 is a cell product comprised of autologous, peripheral blood monocyte-derived, pro inflammatory macrophages, transduced with an adenoviral vector containing an anti-HER2 CAR.
Adoptive T cell–based cellular therapies have led to remarkable advances among patients with hematologic malignancies, but not in those with solid tumors. Among the multiple factors impeding T cell immunotherapy in solid tumors is the inability of T cells, including CAR-T cells, to infiltrate the microenvironment surrounding tumor cells. Macrophages, by contrast, are actively recruited into the tumor microenvironment. While macrophages contain the necessary machinery for phagocytosis and antigen presentation, macrophages in the tumor microenvironment (TME), called tumor-associated macrophages (TAMs), typically evince immunosuppressive rather than antitumor behavior. Thus, macrophages engineered to be proinflammatory may be an ideal vector to administer adoptive cellular therapy in solid tumors.
Please fill out the following form:
*Do not fill out if you are a patient interested in joining the study. Visit the Study Clinic Locations to email the site closest to you.
Study participation could last about 13 months from the screening visit and is separated into 2 groups. Study design includes the following:
Both Groups (7 weeks)
Group 1 (Day 1, 3, & 5)
Group 2 (Day 1)
Group 1 (Day 8 through Week 4)
Group 2 (Day 2 through Week 4)
Both Groups (Weeks 8 through 52)
*Other protocol-defined Inclusion/Exclusion criteria may apply.
For more information, please contact Carisma Therapeutics via email at info@carismatx.com.
Send EmailAdditional study information can also be found on clinicaltrials.gov/NCT04660929
Use the filters, map, and listing to find the nearest study clinic. You can contact the study clinic using the associated email link or phone number.